With the advent of PD-L1 inhibitors for the treatment of solid organ and hematologic malignancies, there have also been discoveries of the drug’s nonspecific activation of the immune system, contributing to cutaneous adverse effects such as vitiligo, pruritus, lichenoid dermatitis, psoriasiform eruptions, and immunobullous dermatoses.5 This evidence concerns the gene CD274 and vitiligo.